Latest news articles

Added 5 minutes ago Drug news

Orexigen Therapeutics sells assets to Nalpropion Pharmaceuticals, Inc..

Orexigen Therapeutics, Inc announced that it has entered into an asset purchase agreement with Nalpropion Pharmaceuticals, Inc. to sell substantially...

Added 5 minutes ago Drug news

Positive data indicate that patients with unilateral knee OA pain treated with Zilretta experienced significant and sustained improvements in pain, function, and knee-related quality of life metrics.- Flexion Terpeutics.

Flexion Therapeutics, Inc. will present positive clinical data from a post-hoc analysis of patients with unilateral knee osteoarthritis (OA) pain...

Added 5 minutes ago Drug news

Results of Phase III ARCTIC trial of durvalumab plus tremelimumab for NSCLC.- AstraZeneca

AstraZeneca and MedImmune, its global biologics research and development arm, announced high-level results from the Phase III ARCTIC trial in...

Added 5 minutes ago Drug news

NEOD 001 development is discontinued for AL Amyloidosis.-Prothena Corpn.

Prothena Corporation plc has announced that the Company is discontinuing development of NEOD 001, an investigational antibody that was being...

Added 1 day ago Drug news

Data Safety Monitoring Board positive recommendation for RESOLVE-IT Phase III trial of elafibranor to proced for NASH.- Genfit.

GENFIT announced that the Data Safety Monitoring Board (DSMB) issued a new positive recommendation for the continuation of the RESOLVE-IT...

Added 5 minutes ago Drug news

Keytruda + Alimta + carboplatin refiled with EMA for metastatic nonsquamous NSCLC.- Merck Inc.

Merck Inc announced that following validation by the European Medicines Agency (EMA), the centralized review process has begun for the...

Added 5 minutes ago Drug news

Post hoc analyses of Phase III studies of galcanezumab shows 50% reduction of migraine headache days.- Eli Lilly.

Eli Lilly and Company announced results from a post-hoc subgroup analysis which demonstrated efficacy of galcanezumab in patients with episodic...

Added 5 minutes ago Drug news

PROMISE 1 phase III trial of ALD 403 show bennfits in longer treatment for episodic migraine.- Alder Biopharma.

Alder BioPharmaceuticals announced new twelve-month data from its PROMISE 1 Phase III clinical trial of ALD 403 (eptinezumab) in episodic...

Added 5 minutes ago Drug news

Study of Vercise DBS System at one year meets endpoint in Parkinsons disease-. Boston Scientific.

Boston Scientific announced one-year data from the INTREPID study, the first and only prospective, double-blind, randomized, sham-controlled, multi-center study of...

Added 1 day ago Drug news

FDA Advisory Commmittee recommends baricitinib 2-mg dose to treat Rheumatoid Arthritis but not 4-mg dose.- Eli Lilly + Incyte Corpn.

Eli Lilly and Company and Incyte Corporation announced that the FDA Arthritis Advisory Committee recommended approval of the 2-mg dose...

Search all news articles